CRISPR Therapeutics (CRSP) Stock Forecast & Price Target

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

$55.56

-2.40 (-4.14%)

(As of 04/17/2024 ET)

CRISPR Therapeutics Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Hold
Based on 17 Analyst Ratings

Analysts' Consensus Price Target

$74.93
34.87% Upside

High Forecast	$112.00
Average Forecast	$74.93
Low Forecast	$30.00

Type	Current Forecast 4/18/23 to 4/17/24	1 Month Ago 3/19/23 to 3/18/24	3 Months Ago 1/18/23 to 1/18/24	1 Year Ago 4/18/22 to 4/18/23
Consensus Rating	Hold	Hold	Hold	Hold
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	9 Buy rating(s)	9 Buy rating(s)	10 Buy rating(s)	10 Buy rating(s)
Hold	6 Hold rating(s)	7 Hold rating(s)	6 Hold rating(s)	8 Hold rating(s)
Sell	2 Sell rating(s)	2 Sell rating(s)	2 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$74.93	$72.94	$68.39	$72.84
Predicted Upside	34.87% Upside	7.28% Upside	24.61% Upside	37.72% Upside

Get CRISPR Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for CRSP and its competitors with MarketBeat's FREE daily newsletter.

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

CRSP Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

CRSP Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

CRISPR Therapeutics Stock vs. The Competition

Type	CRISPR Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	2.41	2.68	2.49
Consensus Rating	Hold	Moderate Buy	Hold
Predicted Upside	34.87% Upside	926.66% Upside	12.24% Upside
News Sentiment Rating	Positive News	Neutral News	Positive News

Recent Analyst Ratings and Stock Forecasts

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
4/11/2024	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$90.00	+45.77%
3/6/2024	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$82.00 ➝ $99.00	+22.24%
2/26/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Underweight ➝ Underweight	$46.00 ➝ $48.00	-43.64%
2/22/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Sector Perform ➝ Sector Perform	$57.00 ➝ $66.00	-26.83%
2/22/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$55.00 ➝ $70.00	-21.92%
2/22/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$61.00 ➝ $80.00	-9.55%
Get the Latest News and Ratings for CRSP and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for CRISPR Therapeutics and its competitors with MarketBeat's FREE daily newsletter.
2/22/2024	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$110.00 ➝ $112.00	+35.91%
2/15/2024	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Peer Perform
12/11/2023	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Market Outperform ➝ Market Outperform	$74.00 ➝ $80.00	+23.95%
12/11/2023	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Market Perform ➝ Underperform	$30.00	-53.52%
12/8/2023	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy
10/17/2023	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	O. Brayer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Neutral
8/17/2023	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Buy	$70.00	+47.03%
8/10/2023	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Outperform	$102.00	+103.80%
8/8/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$62.00 ➝ $63.00	+30.33%
5/30/2023	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Corwin Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$75.00	+15.99%
5/9/2023	VNET Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Reiterates
5/9/2023	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$69.00 ➝ $64.00	+14.37%
4/17/2023	EF Hutton Acquisition Co. I Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy	$75.00	+38.63%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 10:04 PM ET.

CRSP Price Target - Frequently Asked Questions

What is CRISPR Therapeutics's consensus rating and price target?: According to the issued ratings of 17 analysts in the last year, the consensus rating for CRISPR Therapeutics stock is Hold based on the current 2 sell ratings, 6 hold ratings and 9 buy ratings for CRSP. The average twelve-month price prediction for CRISPR Therapeutics is $74.93 with a high price target of $112.00 and a low price target of $30.00. Learn more on CRSP's analyst rating history.
Do Wall Street analysts like CRISPR Therapeutics more than its competitors?: Analysts like CRISPR Therapeutics less than other Medical companies. The consensus rating for CRISPR Therapeutics is Hold while the average consensus rating for medical companies is Moderate Buy. Learn more on how CRSP compares to other companies.
Does CRISPR Therapeutics's stock price have much upside?: According to analysts, CRISPR Therapeutics's stock has a predicted upside of 8.61% based on their 12-month stock forecasts.

What analysts cover CRISPR Therapeutics?: CRISPR Therapeutics has been rated by Barclays, Chardan Capital, Mizuho, Morgan Stanley, Needham & Company LLC, Royal Bank of Canada, Wells Fargo & Company, and Wolfe Research in the past 90 days.

Stock Ratings Reports and Tools

Related Companies:

Today's Ratings:

Top Rated Stocks:

More Ratings Tools:

This page (NASDAQ:CRSP) was last updated on 4/17/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

CRISPR Therapeutics (CRSP) Stock Forecast & Price Target

CRISPR Therapeutics Consensus Analyst Rating and Stock Price Forecast (2024)

Analysts' Consensus Rating

Analysts' Consensus Price Target

CRSP Analyst Ratings By Month

CRSP Price Targets by Month

CRISPR Therapeutics Stock vs. The Competition

Recent Analyst Ratings and Stock Forecasts

CRSP Price Target - Frequently Asked Questions

Stock Ratings Reports and Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info